NEW YORK, Oct. 25 (GenomeWeb News) - PharmacoDesign will use Illumina's BeadStation system and whole-genome genotyping arrays and reagents to study genetic variations in various Korean populations, Illumina said today.
Under a worldwide royalty-bearing exclusive license, Illumina will incorporate biomarkers discovered by PharmacoDesign into proprietary SNP panels.
PharmacoDesign will utilize Illumina's Sentrix Human-1 BeadChip, containing over 100,000 SNP markers, and its Infinium assay for this project.
PharmacoDesign studies diseases that include obesity, cancer, and allergy-induced reactions such as atopy. The company works with large Korean hospitals to prescribe individualized treatments.
Financial details were not disclosed.